Peptide profile
Published Data as of
In a trial in people with HIV and non-alcoholic fatty liver disease (NAFLD), tesamorelin reduced hepatic fat fraction more than placebo over 12 months.1 Other trials in people measured trunk muscle, insulin response and neurocognitive performance.2,3,4 In a trial in adults with type 2 diabetes, insulin response did not change versus placebo.3 In a cognition trial in people with HIV, only a trend appeared, and it was not significant.4
The FDA approved Egrifta, a tesamorelin product, in the US in 2010. Its listed use is reducing excess abdominal fat in adults with HIV and lipodystrophy.8,9
A pooled analysis of two trials in patients with HIV and excess abdominal fat compared tesamorelin with placebo. At week 26, visceral adipose tissue (VAT) changed by -24 square centimeters with tesamorelin. It changed by 2 square centimeters with placebo. The treatment effect on VAT was -15.4%.5
In another trial in patients with HIV, VAT changed by -15.2% with tesamorelin over 26 weeks and by 5% with placebo.6 In a third trial in adults with HIV, VAT changed by -10.9% with tesamorelin over 6 months and by -0.6% with placebo.10
In the pooled trials in patients, abdominal fat under the skin did not change significantly versus placebo. It changed by -2 square centimeters with tesamorelin and 2 square centimeters with placebo.5
In a trial in adults with HIV and abdominal fat accumulation, tesamorelin reduced liver fat more than placebo over 6 months. The median liver fat change was -2% with tesamorelin and 0.9% with placebo. The net treatment effect was -2.9%.11
A second trial in people with HIV and NAFLD ran over 12 months. Tesamorelin reduced hepatic fat fraction (HFF) more than placebo, with an absolute difference of -4.1%. In this trial in people, HFF showed a 37% relative reduction from baseline.1
In a trial in adults with HIV and abdominal obesity, responders were people whose visceral fat fell by 8% or more on tesamorelin. These responders had greater increases than placebo participants in the density of four trunk muscle groups.2 In this trial in people, responders also gained more lean muscle area in all four groups.2
In the same trial in people, lean density rose more in responders in the abdominal muscles, with a coefficient of 1.39 Hounsfield units. The coefficient for the rectus muscles was 1.78 Hounsfield units.2
In this trial in people, the total area of the rectus muscles grew by 0.44 square centimeters more in responders than with placebo. The psoas muscles grew by 0.46 square centimeters more.2
In a trial in adults with type 2 diabetes, tesamorelin did not change relative insulin response versus placebo over 12 weeks.3 In a trial in adults with HIV and abdominal fat, tesamorelin caused no change in glucose parameters.10
In another trial in adults with HIV, fasting glucose rose more with tesamorelin than with placebo at 2 weeks.11 At 6 months in that trial in people, the change in fasting glucose did not differ significantly from placebo. Neither did the 2-hour glucose change.11
In a trial in virally suppressed adults with HIV and abdominal obesity, researchers compared tesamorelin with standard of care. Tesamorelin reduced waist circumference more, with a median difference of -2.7 cm.4 In this trial in people, neurocognitive performance showed a trend toward improvement, but the difference from standard of care was not significant.4
Randomized controlled trials in people studied tesamorelin at 2 mg, given subcutaneously.5,6,11 A dose-ranging randomized controlled trial in people studied 1 mg and 2 mg, also given subcutaneously.12
| Kind | Dose | Species | Route | Design | Source |
|---|---|---|---|---|---|
| Studied dose | 2 mg | people | subcutaneous | randomized controlled trial | [5] |
| Studied dose | 2 mg | people | subcutaneous | randomized controlled trial | [6] |
| Studied dose | 2 mg every day | people | subcutaneous | randomized controlled trial | [10] |
| Studied dose | 2 mg daily | people | subcutaneous | randomized controlled trial | [4] |
| Studied dose | 2 mg | people | subcutaneous | randomized controlled trial | [11] |
| Studied dose | 1 mg | people | subcutaneous | randomized controlled trial | [12] |
| Studied dose | 2 mg | people | subcutaneous | randomized controlled trial | [12] |
| Studied dose | 2 mg daily | people | subcutaneous | randomized controlled trial | [13] |
As of October 30, 2026, PepBank holds 37 publications with findings in people and 5 with findings in animals, by evidence class. The records also list 23 registered trials that test tesamorelin.7 PepBank records 288 results from tesamorelin studies that gave the peptide.7
Tesamorelin is one of the peptides in PepBank, with 42 studies that gave it and reported results.7 The FDA also approved Egrifta SV for the same use in adults with HIV and lipodystrophy. In 2025, it approved Egrifta WR for that use.14,15
The FDA approved Egrifta in the US in 2010 for reducing excess abdominal fat in adults with HIV and lipodystrophy.9 The FDA also approved Egrifta SV for the same use, and it approved Egrifta WR in 2025.14,15 PepBank's regulatory record lists tesamorelin as approved in the US under the Egrifta name, with a 2010 date.8
In pooled trials in patients with HIV and excess abdominal fat, tesamorelin reduced triglycerides versus placebo at week 26. The treatment effect was -12.3%.5 In the same trials in patients, it reduced the cholesterol to HDL ratio, with a treatment effect of -7.2%.5 Another trial in patients found lower triglycerides and a lower cholesterol to HDL ratio versus placebo.6
In pooled trials in patients with HIV, mean IGF-I rose by 108 ng/ml with tesamorelin and changed by -7 ng/ml with placebo.5 In another trial in patients, IGF-I rose 81% with tesamorelin and changed by -5% with placebo.6 In a dose-ranging randomized trial in people, subcutaneous amounts of 1 mg and 2 mg raised IGF-I by 48% and 65%.12
In pooled trials in patients with HIV and excess abdominal fat, tesamorelin improved belly appearance distress.5 Patient and physician ratings of belly profile also improved in those trials in patients.5 In a separate trial in adults with HIV, patient-rated distress and physician-rated belly profile improved versus placebo.10 The pooled trials reported tesamorelin as generally well tolerated in patients.5
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated